Back to today’s briefing

Story perspectives

FDA Tightens COVID Vaccine Approval Standards Amid New Variants

5/27/2025

39 8

Summary

Story summary

The FDA is raising the bar for COVID-19 vaccine approvals, now demanding rigorous trial data for new vaccines aimed at healthy individuals. This move prioritizes safety and effectiveness. Meanwhile, Moderna has introduced an updated vaccine for the LP.8.1 variant, and Novavax has proudly secured full approval for its vaccine for those aged 12 and up.

1 of 1

Story summary

The FDA is raising the bar for COVID-19 vaccine approvals, now demanding rigorous trial data for new vaccines aimed at healthy individuals. This move prioritizes safety and effectiveness. Meanwhile, Moderna has introduced an updated vaccine for the LP.8.1 variant, and Novavax has proudly secured full approval for its vaccine for those aged 12 and up.